Companies ›Financials ›THG.BK

THG.BK — SET (Bangkok) Insurance

Thonburi Healthcare Group PCL

$7,65

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

1,68 %

Op margin

5,4 %

ROE

0,7 %

Net margin

1,1 %

Debt / equity

0,28

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$207,64

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Thonburi Healthcare Group PCL operates in the healthcare facilities and services industry, providing pharmaceutical and healthcare services to patients in Thailand and potentially other markets.

Business. Thonburi Healthcare Group PCL (THG.BK) is a healthcare services and equipment company primarily engaged in pharmaceuticals and healthcare facilities and services. The firm operates on a service-revenue model within the broader healthcare industry. Headquartered in Thailand, the company is listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorFinancials

Industry groupInsurance

Generated · model-assisted

Sell-side consensus

SELL1 analysts

0 buy0 hold1 sell

Avg 12m price target7,20

Analyst recommendations

1 analysts · consensus Sell

Buy0

Hold0

Sell1

12-month price target

7,20

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Sell

1 analysts · indicative

Ownership→

First Trust Advisors L.P.

largest disclosed fund holder

Profitability→

0,7 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning THG.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials · THIS SECTOR−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to THG.BK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Thonburi Healthcare Group PCL (THG.BK) is a healthcare services and equipment company primarily engaged in pharmaceuticals and healthcare facilities and services. The firm operates on a service-revenue model within the broader healthcare industry. Headquartered in Thailand, the company is listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorFinancials

Industry groupInsurance

AI synthesis

GENERATED

Thonburi Healthcare Group PCL maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.28, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.33, suggesting it can cover its short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if cash flow from operations is disrupted.

In terms of profitability, the company's return on equity (ROE) is 0.72%, and its return on assets (ROA) is 0.47%, both of which are below the industry median for healthcare facilities and services. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating margin, calculated as operating income divided by revenue, is 5.45%, which is also below the industry median, indicating that the company is generating less profit per unit of revenue compared to its competitors.

Geographically, the company's revenue is concentrated in Thailand, with no significant international exposure disclosed in the available data. The company operates in a single business segment, which is typical for a healthcare services provider in the region. However, the lack of diversification could expose the company to local economic and regulatory risks.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The operating cash flow of 1.18 billion THB and free cash flow of 399.5 million THB indicate that the company is generating positive cash from operations, but the capital expenditure of -896.55 million THB suggests that the company is investing in its operations to maintain or expand its service offerings. Analysts have assigned a neutral recommendation to the stock, with a mean price target of 7.20 THB, which is unchanged from the median and high/low targets, indicating a lack of consensus on the stock's future performance.

The company's risk profile is characterized by a low dilution risk, with no significant dilution potential identified in the latest financial data. However, the negative net cash position after debt is a red flag, as it could lead to increased borrowing or equity issuance in the future, which could dilute existing shareholders. The company's liquidity risk is moderate, as it has sufficient current assets to cover its short-term liabilities, but the lack of a strong cash buffer could be a concern in a downturn.

Recent events, including the latest financial filing, show that the company is maintaining a stable financial position, with no major one-time charges or restructuring activities reported. The company's credit risk is low, as it has a strong equity base and manageable debt levels. However, the company's exposure to regulatory changes in the healthcare sector could impact its operations and profitability in the future.

Key takeaways

Thonburi Healthcare Group PCL has a conservative capital structure with a debt-to-equity ratio of 0.28.
The company's ROE and ROA are below the industry median, indicating underperformance in capital efficiency.
The company's revenue is concentrated in Thailand, with no significant international exposure.
Analysts have assigned a neutral recommendation to the stock, with a mean price target of 7.20 THB.
The company's liquidity risk is moderate, with a current ratio of 1.33 but a negative net cash position after debt.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$7,65

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$13.44B

Net cashⓘ

-$3.79B

Current ratioⓘ

1.3

Debt / equityⓘ

0.3

ROAⓘ

0.5%

ROEⓘ

0.7%

Cash conversionⓘ

1229.0%

CapEx / revenueⓘ

-9.9%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,36

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-24 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,20
Revenue	—no estimate	—no estimate	10,1B THB
Operating income	—no estimate	—no estimate	349,0M THB

Full-year consensus mean (period as reported by source) · consensus in THB. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy0

Hold0

Sell0

Strong sell1

12-month price target$7,20 · Median $7,20

Low $7,20High $7,20

Operating income · consensus349,0M THB

EPS surprise

−59,0 %

reported vs consensus · miss

Revenue surprise

−9,8 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$7,20

Mean$7,20

Median$7,20

High$7,20

Spot$7,65

−5.9 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin5,4 %Below median

Net Margin1,1 %Bottom quartile

ROE0,7 %Bottom quartile

Capex / Rev-9,9 %Bottom quartile

D/E0,28Below median

Cash Conv12,29Best in class

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-22 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 144 444 sh9 exercises5 insiders

FARBER JEFFREY MExecutive Vice President · Common Stock Option (right to buy) → Common StockDisposed 19 084 @ $115,35exercise · 2026-07-29
FARBER JEFFREY MExecutive Vice President · Common Stock Option (right to buy) → Common StockDisposed 20 379 @ $117,22exercise · 2026-07-29
FARBER JEFFREY MExecutive Vice President · Common Stock Option (right to buy) → Common StockDisposed 26 832 @ $118,54exercise · 2026-07-29
Salvatore Bryan JExecutive Vice President · Common Stock Option (right to buy) → Common StockDisposed 16 394 @ $104,11exercise · 2026-06-03
Kerrigan Dennis FrancisExecutive Vice President · Common Stock Option (right to buy) → Common StockDisposed 6 262 @ $115,35exercise · 2026-05-20
Roche John CDirector, President and CEO · Common Stock Option (right to buy) → Common StockDisposed 24 026 @ $104,11exercise · 2026-05-19
Roche John CDirector, President and CEO · Common Stock Option (right to buy) → Common StockDisposed 9 098 @ $85,87exercise · 2026-05-19
Roche John CDirector, President and CEO · Common Stock Option (right to buy) → Common StockDisposed 18 194 @ $85,87exercise · 2026-05-15
Lowsley DeniseExecutive Vice President · Common Stock Option (right to buy) → Common StockDisposed 4 175 @ $115,35exercise · 2026-05-14

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Thonburi Healthcare Group PCL Market data — financials · 2026-05-29
Thonburi Healthcare Group PCL Market data — analyst estimates · 2026-05-29
Thonburi Healthcare Group PCL Market data — ESG · 2026-05-29

Ownership & reference

Top holders

First Trust Advisors L.P.Investment Managers · as of 2026-03-310,10 %$143M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,09 %$174M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,08 %$175M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,05 %$152M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,03 %$168M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,03 %$104M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,03 %$120M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,03 %$0M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$82M
Invesco QQQ TrustFunds · as of 2026-03-310,01 %$79M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$59M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,01 %$20M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$283M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$669M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$420M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$126M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$59M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$32M
T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$0M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$14M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$41M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$38M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$80M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$12M
EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$7M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$4M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$15M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$3M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$3M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$1M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 14 sellsnet -$8,9M18 insiders · last 365d

FARBER JEFFREY MExecutive Vice President · Common StockOther 49 330 @ $232,34$11,5M · 2026-07-29
FARBER JEFFREY MExecutive Vice President · Common StockOther 19 084 @ $115,35$2,2M · 2026-07-29
FARBER JEFFREY MExecutive Vice President · Common StockOther 26 832 @ $118,54$3,2M · 2026-07-29
FARBER JEFFREY MExecutive Vice President · Common StockOther 20 379 @ $117,22$2,4M · 2026-07-29
Egan CynthiaDirector · Common StockOther 4 · 2026-06-26
Lee Willard TExecutive Vice President · Common StockOther 11 · 2026-06-26
LOVELY DAVID JOHNExecutive Vice President · Common StockOther 11 · 2026-06-26
Norton-Gatto Patricia A.SVP & Princpl. Accntg. Officer · Common StockOther 6 · 2026-06-26
Roche John CDirector, President and CEO · Common StockOther 122 · 2026-06-26
Salvatore Bryan JExecutive Vice President · Common StockOther 25 · 2026-06-26
Ward Elizabeth ADirector · Common StockOther 4 · 2026-06-26
RAMRATH JOSEPH RDirector · Common StockOther 4 · 2026-06-26
Condrin J PaulDirector · Common StockOther 4 · 2026-06-26
Aristeguieta FranciscoDirector · Common StockOther 4 · 2026-06-26
Bradicich KevinDirector · Common StockOther 4 · 2026-06-26
Donnell William E.Director · Common StockOther 4 · 2026-06-26
Bunting Theodore H JRDirector · Common StockOther 4 · 2026-06-26
Carlin Jane DDirector · Common StockOther 4 · 2026-06-26
LANE KATHY SDirector · Common StockOther 4 · 2026-06-26
Salvatore Bryan JExecutive Vice President · Common StockSold 16 394 @ $185,76$3,0M · 2026-06-03
Salvatore Bryan JExecutive Vice President · Common StockOther 16 394 @ $104,11$1,7M · 2026-06-03
Aristeguieta FranciscoDirector · Common StockSold 1 000 @ $195,37$195K · 2026-05-21
Roche John CDirector, President and CEO · Common StockSold 5 145 @ $194,05$998K · 2026-05-20
Roche John CDirector, President and CEO · Common StockSold 3 152 @ $193,21$609K · 2026-05-20
Roche John CDirector, President and CEO · Common StockSold 61 @ $194,77$12K · 2026-05-20

Short positioning

1.2Mshares short+6.8% vs prior

3.55days to cover

60.0%short of daily vol

9.0Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

THG.BKCanonical

SET (Bangkok) · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 7.6%Derived (calculated)
Return on equity (FY 2025-12-31): 18.5%Derived (calculated)
Net margin (FY 2025-12-31): 10.0%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 46.1%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 3.74xDerived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 55.2%Derived (calculated)
Return on assets (FY 2025-12-31): 3.9%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 16.8%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 10.9%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 25.7%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 43.5%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 157.8%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 55.5%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -24.5%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 56.1%Derived (calculated)
Capex (annual): USD 7.7MSEC XBRL filing
Operating cash flow (annual): USD 1.18BSEC XBRL filing
Revenue (annual): USD 6.59BSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES 18SEC XBRL filing
Pre-tax income (annual): USD 843.8MSEC XBRL filing
Cash & equivalents (annual): USD 1.12BSEC XBRL filing
Net income (annual): USD 662.5MSEC XBRL filing
Long-term debt (annual): USD 843.3MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-29INSIDERFARBER JEFFREY M transacted 49.3k sh — Executive Vice President ~$11.46M

2026-07-29INSIDERFARBER JEFFREY M transacted 19.1k sh — Executive Vice President ~$2.20M

2026-07-29INSIDERFARBER JEFFREY M transacted 26.8k sh — Executive Vice President ~$3.18M

2026-07-29INSIDERFARBER JEFFREY M transacted 20.4k sh — Executive Vice President ~$2.39M

2026-07-29INSIDERFARBER JEFFREY M disposed of 20.4k sh Common Stock Option (right to buy) — Executive Vice President

2026-07-29INSIDERFARBER JEFFREY M disposed of 26.8k sh Common Stock Option (right to buy) — Executive Vice President

2026-07-29INSIDERFARBER JEFFREY M disposed of 19.1k sh Common Stock Option (right to buy) — Executive Vice President

2026-07-28 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-27 03:14 UTCHOLDERInstitutional holding changed

2026-06-27 03:14 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-26 03:13 UTCHOLDERInstitutional holding changed

2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-26INSIDEREgan Cynthia transacted 4 sh — Director

2026-06-26INSIDERLee Willard T transacted 11 sh — Executive Vice President

2026-06-26INSIDERLOVELY DAVID JOHN transacted 11 sh — Executive Vice President

2026-06-26INSIDERNorton-Gatto Patricia A. transacted 6 sh — SVP & Princpl. Accntg. Officer

2026-06-26INSIDERRoche John C transacted 122 sh — Director, President and CEO

2026-06-26INSIDERSalvatore Bryan J transacted 25 sh — Executive Vice President

2026-06-26INSIDERWard Elizabeth A transacted 4 sh — Director

2026-06-26INSIDERRAMRATH JOSEPH R transacted 4 sh — Director

2026-06-26INSIDERCondrin J Paul transacted 4 sh — Director

2026-06-26INSIDERAristeguieta Francisco transacted 4 sh — Director

2026-06-26INSIDERBradicich Kevin transacted 4 sh — Director

2026-06-26INSIDERDonnell William E. transacted 4 sh — Director

2026-06-26INSIDERBunting Theodore H JR transacted 4 sh — Director

2026-06-26INSIDERCarlin Jane D transacted 4 sh — Director

2026-06-26INSIDERLANE KATHY S transacted 4 sh — Director

2026-06-24 07:41 UTCNEWSTHG revenue rises on beauty and nutrition strength → The UK e-commerce group's results highlight resilient consumer spending in personal care segments despite broader macro headwinds.

2026-06-03 00:00 UTCINSIDER3 insider transactions — 2026-06 · net sell $1.3M 1 derivative

2026-06-03INSIDERSalvatore Bryan J sold 16.4k sh — Executive Vice President ~$3.05M

2026-06-03INSIDERSalvatore Bryan J transacted 16.4k sh — Executive Vice President ~$1.71M

2026-06-03INSIDERSalvatore Bryan J disposed of 16.4k sh Common Stock Option (right to buy) — Executive Vice President

2026-05-21 00:00 UTCINSIDER35 insider transactions — 2026-05 · net sell $7.2M 5 derivative

2026-05-21INSIDERAristeguieta Francisco sold 1.0k sh — Director ~$195k

2026-05-20INSIDERRoche John C sold 5.1k sh — Director, President and CEO ~$998k

2026-05-20INSIDERRoche John C sold 3.2k sh — Director, President and CEO ~$609k

2026-05-20INSIDERRoche John C sold 61 sh — Director, President and CEO ~$12k

Showing the 40 most recent of 59 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread